tbuckley/cabot-search huggingface dataset:
Short-term Suicide Risk After Psychiatric Hospital Discharge
Authors: Mark Olfson, Melanie Wall, Shuai Wang, Stephen Crystal, Shang-Min Liu, Tobias Gerhard, Carlos Blanco
Journal: JAMA Psychiatry (2016)

Although psychiatric inpatients are recognized to be at increased risk for suicide immediately after hospital discharge, little is known about the extent to which their short-term suicide risk varies across groups with major psychiatric disorders.To describe the risk for suicide during the 90 days after hospital discharge for adults with first-listed diagnoses of depressive disorder, bipolar disorder, schizophrenia, substance use disorder, and other mental disorders in relation to inpatients with diagnoses of nonmental disorders and the general population.This national retrospective longitudinal cohort included inpatients aged 18 to 64 years in the Medicaid program who were discharged with a first-listed diagnosis of a mental disorder (depressive disorder, bipolar disorder, schizophrenia, substance use disorder, and other mental disorder) and a 10% random sample of inpatients with diagnoses of nonmental disorders. The cohort included 770 643 adults in the mental disorder cohort, 1 090 551 adults in the nonmental disorder cohort, and 370 deaths from suicide from January 1, 2001, to December 31, 2007. Data were analyzed from March 5, 2015, to June 6, 2016.Suicide rates per 100 000 person-years were determined for each study group during the 90 days after hospital discharge and the demographically matched US general population. Adjusted hazard ratios (ARHs) of short-term suicide after hospital discharge were also estimated by Cox proportional hazards regression models. Information on suicide as a cause of death was obtained from the National Death Index.In the overall population of 1 861 194 adults (27% men; 73% women; mean [SD] age, 35.4 [13.1] years), suicide rates for the cohorts with depressive disorder (235.1 per 100 000 person-years), bipolar disorder (216.0 per 100 000 person-years), schizophrenia (168.3 per 100 000 person-years), substance use disorder (116.5 per 100 000 person-years), and other mental disorders (160.4 per 100 000 person-years) were substantially higher than corresponding rates for the cohort with nonmental disorders (11.6 per 100 000 person-years) or the US general population (14.2 per 100 000 person-years). Among the cohort with mental disorders, AHRs of suicide were associated with inpatient diagnosis of depressive disorder (AHR, 2.0; 95% CI, 1.4-2.8; reference cohort, substance use disorder), an outpatient diagnosis of schizophrenia (AHR, 1.6; 95% CI, 1.1-2.2), an outpatient diagnosis of bipolar disorder (AHR, 1.6; 95% CI, 1.2-2.1), and an absence of any outpatient health care in the 6 months preceding hospital admission (AHR, 1.7; 95% CI, 1.2-2.5).After psychiatric hospital discharge, adults with complex psychopathologic disorders with prominent depressive features, especially patients who are not tied into a system of health care, appear to have a particularly high short-term risk for suicide.
Preclinical Study to Sensitize Acute Lymphoblastic Leukemia Primary Cells by Combined mTOR and BCL-2 Inhibition with CCI-779 and ABT-737.
Authors: Maria Rosaria Ricciardi, Samantha Decandia, Paola Bergamo, Cinzia De Benedictis, Antonella Vitale, Anna Maria Testi, Joanna Fei, Maria Teresa Petrucci, Michele Milella, Robin Foà, Agostino Tafuri
Journal: Blood (2009)
Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction
Authors: Bridgette A. Kanz, Megan H. Pollack, Romany Johnpulle, Igor Puzanov, Leora Horn, Alicia Morgans, Jeffrey A. Sosman, Suthee Rapisuwon, R. Martin Conry, Zeynep Eroglu, Douglas B. Johnson
Journal: Journal for ImmunoTherapy of Cancer (2016)

Anti-PD-1 therapy is increasingly used in various advanced malignancies. Patients with baseline organ dysfunction are largely excluded from clinical trials. Therefore it is unclear whether anti-PD-1 therapy is safe or effective in this setting. Further, these patients are often not candidates for other anti-cancer therapies, highlighting their need for active treatment options.We performed a retrospective analysis of patients from multiple centers with advanced solid tumors and baseline organ dysfunction who received anti-PD-1 therapy. Organ dysfunction was defined as cardiac (left ventricular ejection fraction ≤45 %), renal (creatinine ≥2 mg/dL or GFR ≤30 ml/min) or hepatic dysfunction (evidence of cirrhosis on imaging or AST, ALT or bilirubin ≥3x ULN). We assessed change in organ dysfunction, immune related adverse events (irAEs), response rate, progression free survival (PFS) and overall survival (OS).We identified 27 patients eligible for inclusion with the following diseases: renal cell carcinoma (n = 8), melanoma (10), non-small cell lung cancer (3), small cell lung cancer (2) and urothelial bladder cancer (4). Baseline organ dysfunction included renal dysfunction (n = 17), hepatic dysfunction (7), cardiac dysfunction (11), including >1 organ dysfunction (8). Worsening organ dysfunction requiring hospitalization or dose delays occurred in 8 patients (30 %) although in most cases this was thought not-drug related and resolved with supportive care. Grade 3 irAEs occurred in 2 pts (7 %; hepatitis and colitis). Thirteen of 27 patients had ongoing treatment benefit (objective response or stable disease) at data collection (48 %). Eleven patients had primary progressive disease (41 %), 11 had stable disease (41 %), 4 had partial responses (15 %), and one had a complete response (4 %). Overall, median PFS was 168 days. Median OS was not reached.In our experience, anti-PD-1 agents in this group of patients with cardiac, hepatic or renal dysfunction were associated with tolerable irAEs and infrequent manageable worsening of organ dysfunction. Further, objective responses and prolonged PFS were observed in a number of patients. Thus, patients with baseline organ dysfunction may be considered for anti-PD-1 therapy with appropriate clinical monitoring.
Impact of Basal Comorbidities on the Overall Benefit of DAA Therapy in Hepatitis C
Authors: J. Ampuero, C. Jimeno, N. Palomo, R. Quiles, A. Ortega, G. Ontanilla, P. Cordero, J.M. Rosales, M. Hernandez, F.J. Serrano, M. Bonacci, M. Maraver, L. Grande, X. Forns, M. De la Mata, J.L. Calleja, J.M. Navarro, I. Carmona, J.M. Pascasio, R. Andrade, J. Salmeron, M. Buti, J. Crespo, M. Romero-Gomez
Journal: Journal of Hepatology (2016)
Metabolic Reprogramming toward Awarburg Phenotype Characterizes Early Phases of Hepatic Carcinogenesis
Authors: M.A. Kowalik, G. Guzzo, A. Morandi, A. Perra, S. Menegon, I. Masgras, E. Trevisan, M.M. Angioni, F. Fornari, L. Quagliata, G.M. Ledda-Columbano, L. Gramantieri, L. Terracciano, S. Giordano, P. Chiarugi, A. Rasola, A. Columbano
Journal: Journal of Hepatology (2016)
Antiviral Treatment in Patients with Advanced Hcv Cirrhosis Using Sofosbuvir and Ledipasvir/Daclatasvir with or without Ribavirin - 6 and 12 Month Outcomes Compared to Untreated Patients
Authors: M.C.M. Cheung, G.R. Foster, W.L. Irving, A.J. Walker, B.E. Hudson, S. Verma, J. McLauchlan, D.J. Mutimer, A. Brown, W. Gelson, D. MacDonald, K. Agarwal
Journal: Journal of Hepatology (2016)
Effect of race/ethnicity and treatment delay on breast cancer survival
Authors: S. Sheinfeld Gorin, J. E. Heck, B. Cheng, S. Smith
Journal: Journal of Clinical Oncology (2006)

6063 Background: Several papers have examined the relationship between treatment delay and survival among patients who are diagnosed with cancer. None has yet relied on a large, population-based dataset to systematically examine survival among women within different ethnic/racial groups who delay breast cancer treatment. Methods: Subjects were 49,865 female Medicare enrollees age 65 and older who were diagnosed with breast cancer between 1992 and 1999 and identified by the Surveillance, Epidemiology, and End Results (SEER) program. Dates of their health care visits were identified through the linkage of SEER with Medicare claims data. Mortality from breast cancer was assessed through linkage with death certificates. Propensity score analyses that compared patients matched according to their propensity to receive treatment were used to balance patient characteristics between treatment groups, as would occur in a randomized clinical trial. Results: A propensity score analysis and a Cox proportional hazards model of survival (with adjustments for ER/PR status, treatment type, race/ethnicity, stage, age, comorbidities, marital status, poverty status, geographic location, and average number of service contacts) revealed that subjects with 1-month delay in the start of treatment had a reduced likelihood of survival (adjusted HR=1.17, 95% CI, 1.06–1.30) relative to those with less delay. Blacks had significantly lessened survival than women in other races/ethnicities (adjusted HR=1.23, 95% CI, 1.00–1.52). Receipt of radiation (adjusted HR=1.45, 95% CI, 1.24–1.69), chemotherapy (adjusted HR=1.73, 95% CI, 1.51–1.99), stage three diagnosis (adjusted HR=1.35, 95% CI, 1.08–1.70), being age 70 or older (adjusted HR=1.24, 95% CI, 1.09–1.41), or having 2 or more comorbidities (adjusted HR=1.47, 95% CI, 1.12–1.92) also predicted reduced survival from breast cancer. Conclusions: One month delay in accessing breast cancer treatment has a clear relationship to reduced survival, particularly among older, later-stage, comorbid black women who receive chemotherapy or radiation. Mechanisms for rapid access to treatment, using both provider- and system-based strategies, are recommended for these women who are at increased risk for breast cancer-related mortality. No significant financial relationships to disclose.
Dasatinib in Children and Adolescents with Relapsed or Refractory Leukemia: Interim Results of the CA180-018 Phase I Study from the ITCC Consortium.
Authors: C. Michel Zwaan, Carmelo Rizzari, Vincent H.J. van der Velden, Berna Beverloo, M. L. den Boer, Andre Baruchel, Francoise Mechinaud, Donna Lancaster, Yousif Matloub, Dominique Derreumaux, Rob Pieters, Pamela Kearns
Journal: Blood (2008)
Autoimmune Hepatitis is Associated with Significant Alterations of the Circulating Innate Lymphoid Cell Pool and Displays Elevated Markers of Bacterial Translocation
Authors: F. Goeser, B. Krämer, P. Lutz, D. Kaczmarek, C. Finnemann, S. Fazeli, M. Parcina, C.P. Strassburg, A. Hörauf, I. Bekeredjian-Ding, U. Spengler, J. Nattermann
Journal: Journal of Hepatology (2016)
Should we keep using Ribavirin to Treat Hepatitis C Recurrence after Liver Transplantation? Results from the CO23 ANRS Cupilt Study
Authors: P. Houssel-Debry, C. Duvoux, A. Coilly, C. Fougerou-Leurent, C. Jezequel, V. De Ledinghen, S. Radenne, N. Kamar, V. Leroy, V. Di Martino, L. D’Alteroche, V. Canva, F. Conti, J. Dumortier, H. Montialoux, P. Lebray, D. Botta-Fridlund, R. Anty, C. Moreno, C. Silvain, C. Besch, P. Perre, F. Durand, A. Abergel, F. Habersetzer, M. Debette-Gratien, A. Rohel, A. Diallo, E. Rossignol, A. Veislinger, H. Danjou, J.-C. Duclos-Vallee, G.-P. Pageaux
Journal: Journal of Hepatology (2016)
Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy
Authors: Klaus Okkenhaug, Mariona Graupera, Bart Vanhaesebroeck
Journal: Cancer Discovery (2016)

The PI3K pathway is hyperactivated in most cancers, yet the capacity of PI3K inhibitors to induce tumor cell death is limited. The efficacy of PI3K inhibition can also derive from interference with the cancer cells' ability to respond to stromal signals, as illustrated by the approved PI3Kδ inhibitor idelalisib in B-cell malignancies. Inhibition of the leukocyte-enriched PI3Kδ or PI3Kγ may unleash antitumor T-cell responses by inhibiting regulatory T cells and immune-suppressive myeloid cells. Moreover, tumor angiogenesis may be targeted by PI3K inhibitors to enhance cancer therapy. Future work should therefore also explore the effects of PI3K inhibitors on the tumor stroma, in addition to their cancer cell-intrinsic impact.
The CGAS-Sting Pathway Exhibits Antiviral Activity against Hepatitis B Virus Infection
Authors: S.-A. Yim, L. Heydmann, E. Verrier, S. Durand, J. Kozubek, T. Croonenborghs, M. Zeisel, N. Pochet, C. Schuster, T.F. Baumert
Journal: Journal of Hepatology (2016)
The prognostic importance of "Detection Mode" and "Palpability" in primary operable grade 2 breast cancers
Authors: B. Van Calster, X. Zhang, T. Vandorpe, Erik Van Limbergen, As. Dieudonne, K. Leunen, Ann Smeets, Frédéric Amant, Patrick Berteloot, Caroline Weltens, Hilde Janssen, Stéphanie Peeters, Hans Wildiers, Robert Paridaens, Chantal Van Ongeval, Andreas Van Steen, Ignace Vergote, P. Moerman, Rose Christiaens, Patrick Neven
Journal: Cancer Research (2010)
All-Trans Retinoic Acid Accelerates Migration of MOLT3 to SDF-1 α/CXCL12 through the Phosphatidylinositol 3 Kinase (PI3K)/Akt Pathway.
Authors: Shiro Jimi, Taichi Matsumoto, Junji Suzumiya, Shuji Hara, Yasushi Takamatsu, Kazuo Tamura
Journal: Blood (2006)
Effect of <i>KRAS</i> and <i>NRAS</i> mutations on treatment outcomes in patients with metastatic colorectal cancer (mCRC) treated first-line with cetuximab plus FOLFOX4: New results from the OPUS study.
Authors: Sabine Tejpar, Heinz-Josef Lenz, Claus-Henning Köhne, Volker Heinemann, Fortunato Ciardiello, Regina Esser, Frank Beier, Christopher Stroh, Klaus Duecker, Carsten Bokemeyer
Journal: Journal of Clinical Oncology (2014)

LBA444 Background: Patients with KRAS exon 2 codon 12/13 wild-type (wt) mCRC benefit significantly from the addition of cetuximab to first-line FOLFOX4 in relation to response and progression-free survival. Patients with KRAS exon 2 codon 12/13 mutations show no benefit with a trend to worse clinical outcomes. Methods: Tumors from OPUS study patients previously defined as KRAS codon 12/13 wt (n=179) were screened for specific mutations in KRAS exons 3 and 4 (8) and NRAS exons 2, 3, and 4 (18) using BEAMing technology. Treatment outcomes were assessed according to mutation status. Results: RAS tumor mutation status was evaluable for 118/179 (66%) patients. Mutations at the screened loci were detected in 36 (31%) patients. In the RAS wt population, there was benefit associated with the addition of cetuximab to FOLFOX4 (Table). In the overall RAS-mutant population, there was less favorable clinical outcome and no benefit from the addition of cetuximab to FOLFOX4. Conclusions: Patients with mCRC harboring any activating mutation of KRAS or NRAS are unlikely to benefit from the addition of cetuximab to FOLFOX4. Definitive conclusions for patients with new tumor mutations cannot be drawn due to low patient numbers. Restricting cetuximab administration to patients with tumors wt at all such loci might enable the further tailoring of therapy to maximize patient benefit. [Table: see text]
Endothelial Dysfunction, Macrophage Dysfunction and Emerging Cardiovascular Risk Factors in Patients with Hepatitis C Virus Infection Characterization and Potential Reversibility with Direct Acting Antiviral Agents
Authors: S. Llerena, C. Perello, M. Hernandez, M.J. Garcia, D. Ramos, A. Estebanez, J. Cabezas, A. Cuadrado, M. López-Hoyos, J.L. Calleja, J. Crespo
Journal: Journal of Hepatology (2016)
Total thyroidectomy versus thyroid lobectomy for papillary thyroid cancer: Comparative analysis after propensity score matching: A multicenter study
Authors: Sayaka Kuba, Kosho Yamanouchi, Naomi Hayashida, Shigeto Maeda, Toshiyuki Adachi, Chika Sakimura, Fusako Kawakami, Hiroshi Yano, Megumi Matsumoto, Ryota Otsubo, Shuntaro Sato, Hikaru Fujioka, Tamotsu Kuroki, Takeshi Nagayasu, Susumu Eguchi
Journal: International Journal of Surgery (2016)
Norfloxacin Estimulates Treg-Mediated Modulation of Proinflammatory Signalling in Experimental Cirrhosis
Authors: I.N. Gomez-Hurtado, O. Juanola, P. Zapater, A. Moratalla, J.M. Gonzalez-Navajas, J. Such, R. Frances
Journal: Journal of Hepatology (2016)
Prognostic Factors for Thrombosis-Free Survival and Overall Survival in Polycytemia Vera: A Retrospective Analysis of 623 Patients Series with Long Follow-up
Authors: Alessandro Andriani, Roberto Latagliata, Michele Cedrone, Ambra Diveroli, Francesca Spirito, Carla Ruscio, Sabrina Leonetti Crescenzi, Raffaele Porrini, Jonny Di Giandomenico, Nicoletta Villivà, Antonio Spadea, Angela Rago, Cinzia De Gregoris, Gloria Pessina, Marianna De Muro, Stefano Felici, Massimo Breccia, Enrico Montefusco, Antonino Bagnato, Barbara Anaclerico, Giuseppe Cimino, Ignazio Majolino, Giuliana Alimena, Marco Montanaro
Journal: Blood (2014)
Are Non Invasive Test Good Enough to Predict Gastroesophageal Varices in Patients with Compensated Advanced Chronic Liver Disease?
Authors: M.L. Gomez, E.L. Herrera, J. De la Revilla Negro, N.F. Puga, M.T. Marugán, M.H. Conde, C.F. Carrillo, F.P. Renedo, J.L. Martinez Porras, J.L. Calleja Panero
Journal: Journal of Hepatology (2016)
Randomized Trial of Telbivudine versus Entecavir in Reducing Serum HBsAg Levels in HBsAg-Positive Entecavir-Treated Patients who Have Achieved HBV DNA Undetectability by Preceding Entecavir Treatment
Authors: Y.-S. Lim, J. An, G.-A. Kim, H.D. Kim, H.C. Lee, J.H. Shim
Journal: Journal of Hepatology (2016)
Transduction of Hepatic Stellate Cells with Genes of HGF and FGF4 before Transplantation Enhances Repopulation of Transplanted Cells in Damaged Rat Liver
Authors: A. Gumerova, A. Titova, E. Sharipova, G. Burganova, G. Pevnev, A. Shafigullina, I. Gazizov, M. Mavlikeev, M. Kaligin, M. Titova, A. Kiassov
Journal: Journal of Hepatology (2016)
Expression Proteomics As Surrogate Biomarkers For Early Treatment Response In Chronic Myeloid Leukemia (CML) Patients
Authors: Ayodele Alaiya, Naeem Chaudhri, Tarek Owaidah, Jonathan Fox, Zakia Shinwari, Eman Barhoush, Fahad Alsharif, Said Y Mohamed, Walid Rasheed, Feras Alfraih, Mahmoud Aljurf
Journal: Blood (2013)
Sirtuin 1 activation alleviates cholestatic liver injury in a cholic acid–fed mouse model of cholestasis
Authors: Supriya R. Kulkarni, Carol J. Soroka, Lee R. Hagey, James L. Boyer
Journal: Hepatology (2016)

Sirtuin1 (Sirt1; mammalian homolog of Saccharomyces cerevisiae enzyme Sir2) is a transcriptional and transactivational regulator of murine farnesoid X receptor (Fxr), which is the primary bile acid (BA) sensor, and critical regulator of BA metabolism in physiological and pathophysiological conditions. Previous studies have suggested compromised Sirt1 expression in rodent models of cholestatic liver injury. We hypothesized that Sirt1 could be potentially targeted to alleviate cholestatic liver injury. In cultured primary human hepatocytes, SIRT1 messenger RNA was down‐regulated after GCA treatment, potentially through induction of microRNA (miR)‐34a, whereas tauroursodeoxycholic acid induced SIRT1 expression without affecting miR‐34a expression. Sirt1 expression was also significantly down‐regulated in three mouse models of liver injury (bile duct ligation, 1% cholic acid [CA] fed, and the Mdr2 −/− mouse). Mice fed CA diet also demonstrated hepatic FXR hyperacetylation and induction of the Janus kinase/p53 pathway. Mice fed a CA diet and concurrently administered the Sirt1 activator, SRT1720 (50 mg/kg/day, orally), demonstrated 40% and 45% decrease in plasma alanine aminotransferase and BA levels, respectively. SRT1720 increased hepatic BA hydrophilicity by increasing tri‐ and tetrahydroxylated and decreasing the dihydroxylated BA fraction. SRT1720 administration also inhibited hepatic BA synthesis, potentially through ileal fibroblast growth factor 15– and Fxr‐mediated inhibition of cytochrome p450 (Cyp) 7a1 and Cyp27a1, along with increased hepatic BA hydroxylation in association with Cyp2b10 induction. SRT1720 administration significantly induced renal multidrug resistance‐associated protein 2 and 4, peroxisome proliferator‐activated receptor gamma coactivator 1‐α, and constitutive androstance receptor expression along with ∼2‐fold increase in urinary BA concentrations. Conclusion : SRT1720 administration alleviates cholestatic liver injury in mice by increasing hydrophilicity of hepatic BA composition and decreasing plasma BA concentration through increased BA excretion into urine. Thus, use of small‐molecule activators of Sirt1 presents a novel therapeutic target for cholestatic liver injury. (H epatology 2016;64:2151‐2164).
Comprehensive Proteomic Study of Hepatoblastoma: Identification of a Prognostic Signature and Deregulated Pathways
Authors: M. Simon, M. Azkargorta, L. Guerra, L. Nonell, M. López-Santamaria, M. Garrido, M.E. Mateos, C. Belendez, D. Plaza, F. Hernandez, M. Mendiola, I. Ojanguren, M. Childs, P. Czauderna, R. Maibach, B. Morland, M.A. Buendia, F. Elortza, R. Planas, M.-R. Sarrias, M. Sala, C. Armengol
Journal: Journal of Hepatology (2016)
Extended analysis of a validated urine-exosome signature to predict high grade prostate cancer on initial biopsy: Performance across multiple sub-groups.
Authors: Michael Donovan, Stefan Bentink, Mikkel Noerholm, Vince O'Neill, Johan Skog
Journal: Journal of Clinical Oncology (2016)

42 Background: We recently completed a prospective observational clinical trial of a first-catch urine exosome gene expression signature (ExoIntelliScore Prostate) to predict high-grade prostate cancer, HGPCA (&gt;/=GS7) on initial biopsy. The assay accurately predicted HGPCA with an NPV&gt;90% for an intended use popuation: men &gt;/= 50 years with an equivocal PSA of 2-10 ng/mL presenting for their first biopsy. Given the current high prostate biopsy rate and potential impact of race, we sought to further understand performance of the assay by constructing sub-cohorts from the validation study. Methods: Utilizing the ExoIntelliScore Prostate result and clinical data from the 519 patient intended use clinical validation cohort (IU), we constructed several subgroups including: i. prior negative (A, n=149), ii. combined prior negative + initial biopsy (B, n=668) and African Americans, AA (C, n=87). Area under the curve (AUC), NPV, PPV, sensitivity and specificity with validated cut-point assess performance. Results: There was demographic comparability between the initial intended use (IU) and various subgroups, i.e., prior negative (A), combined prior negative and initial biopsy (B) and African Americans (C) with some exceptions observed (bold) for AA patients; family history (IU, 23%; A: 27%, B: 24%, C: 30%; positive biopsy rate (IU, 48%; A: 34%, B: 45%, C:52%; and &gt;/= GS7 (IU, 28%; A: 13%, B: 27%; C: 34%). The AUC range for ExoIntelliscore Prostate + standard of care (i.e., age, race, PSA and family history) between IU and A, B subgroups was 0.72-0.74; AUC for AA was 0.62, except for prior negative biopsy AA patients, AUC 0.80; supporting importance of prior negative biopsy. Of note, applying the ExoIntelliscore Prostate cut-point, A, B yielded an NPV of 91%; including NPV of 89% for AA (initial biopsy) and NPV of 91% for AA with initial + prior negative biopsy. Conclusions: The ExoIntelliScore Prostate performed equally well in men with or without a prior negative biopsy with comparable results also seen for African Americans. Additional confirmatory studies with more patients is necessary to confirm initial observations.
38P Single-nucleotide polymorphisms of DPYD predict adverse events associated with 5-fluorouracil in patients with gastrointestinal cancer
Authors: S. Ohnuma, M. Toshima, K. Miura, K. Kudoh, M. Ishida, H. Karasawa, H. Musha, F. Motoi, T. Naitoh, M. Unno
Journal: Annals of Oncology (2015)
Modified Fractionation Radiotherapy versus Conventional Radiotherapy for Unresected Non-Small Cell Lung Cancer Patients: A Cost-Effectiveness Analysis
Authors: D. De Ruysscher, B.L.T. Ramaekers, M.A. Joore, B. Lueza, J. Bonastre, A. Mauguen, J. Pignon, C. Le Pechoux, J.P. Grutters
Journal: Annals of Oncology (2012)
Global Strain by Echocardiography Is Superior to Ejection Fraction to Predict Ventricular Arrhythmias After Myocardial Infarction
Authors: Kristina H Haugaa, Bjornar L Grenne, Jens-Uwe Voigt, Anca-Rezeda Florian, Benthe Sjoli, Harald Brunvand, Christian H Eek, Walter Desmet, Jesper H Svendsen, Otto A Smiseth, Thor Edvardsen
Journal: Circulation (2011)